Overall survival, lines of therapy, and strategizing with your doctor about your treatments are some of the basic skills covered in this week’s Myeloma Basics videos.

Below are some video excerpts from our HealthTree University curriculum to help you learn more about these important areas of your disease.

If you register in HealthTree to use HealthTree University (where you can watch these same videos), you can save and keep track of your progress, get points for answering quiz questions, bookmark videos, take notes, earn prizes [COMING SOON], and get access to all the other features of HealthTree.

join healthtree

3.06 - When should patients have strategy talks with their doctor?

Featuring:

• Aaron Rosenberg, MD, MS of UC Davis Comprehensive Cancer Center

3.07 - Why should an individual get a second opinion before choosing a treatment option?

Featuring:

• Omar Nadeem, MD of Dana-Farber Cancer Institute

3.08 - What should a myeloma patient consider when choosing a treatment option?

Featuring:

• Omar Nadeem, MD of Dana-Farber Cancer Institute

3.09 - How is a line of therapy defined?

Featuring:

• Omar Nadeem, MD of Dana-Farber Cancer Institute

3.1 - What is the difference between progression free survival (PFS) and overall survival (OS)?

Featuring:

• Dan Vogl, MD, MSCE of Penn Medicine - Abramson Cancer Center
• Philip McCarthy, MD of Roswell Park Comprehensive Cancer Center

Want more?

We have over 200 HealthTree University videos online at university.healthtree.org! Learn the basics (and the not-so-basics) of myeloma from some of the top myeloma doctors in the world!

Other HealthTree University Classes:

1. Myeloma Basics Part 1
2. Myeloma Basics Part 2
3. Myeloma Basics Part 3
4. Building Your HealthCare Team
5. Becoming an Empowered Patient
6. Starting Myeloma Treatment
7. Autologous Stem Cell Transplant (ASCT)
8. Precursor Conditions
9. Relapsed and Refractory MM Treatment
10. Myeloma Bone Disease
11. Testing, Monitoring MM Markers
12. [BETA] Multiple Myeloma Genetics and Precision Medicine
13. Classes of Myeloma Drugs
14. [BETA] COVID-19 and Multiple Myeloma